Electroporation and the associated phenomenon of electrofusion have been widely adapted as tools to a broad range of biomedical research and therapy. In this article, we summarize our adaptation of the electroporation and electrofusion technology in two fronts of cancer research and treatment. The first is genetic manipulation of hematopoietic cells for the purpose of cancer treatment. High efficiency transfection methods have been developed to transfect NK cells, peripheral blood stem cells, and bone marrow derived dendritic cells. Hybrids of tumor cells and bone marrow derived dendritic cells have been formed by electrofusion for the purpose of tumor vaccines. The second front is the use of transcutaneous electroporation to deliver anticancer drugs and vaccines across the skin. Methods to extend the upper molecular weight limit of transcutaneous electroporation have been developed. The pro-photosensitizer drug, δ-amino levulinic acid, the anticancer drug methotrexate, and peptide vaccines designed for cancer prevention and immunotherapy have been delivered transcutaneously by electroporation. These studies hold promise for the treatment of cancers in human.
KinositaK. and TsongT. Y.Formation and reealing of pores of controlled sizes in human erythrocyte membranes. Nature268, 438–441 (1975).
4.
HellerL., JaroszeskiM. J., CoppolaD., PottingerC., GilbertR., HellerR.Electrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivo. Gene Ther.7, 826–9 (2000).
5.
RolsM. P., DelteilC., GolzioM., DumondP., CrosS. and TeissieJ.In vivo electrically mediated protein and gene transfer in murine melanoma. Nature-Biotechnology16, 168–171 (1998).
6.
WellsJ. M., LiL. H., SenA., JahreisG. P. and HuiS. W.Electroporation-Enhanced Gene Delivery in Mammary Tumors. Gene Therapy7, 541–7 (2000).
7.
MirL. M., OrlowskiS.The basis of electrochemotherapy. In Methods in Molecular Medicine: Electrochemotherapy, Electrogenetherapy and Transdermal Drug Delivery, pp 99–118, eds, JaroszeskiM. J., HellerR. and GilbertR., Humana Press, Totowa, NJ. (1999).
8.
HellerR., GilbertR., JaroszeskiM. J.Electrochemotherapy: An emerging drug delivery method for the treatment of cancer. Adv Drug Deliv Rev.7, 185–197. (1997).
9.
PrausnitzM. R., BoseV. G., LangerR., WeaverJ. C.Electroporation of mammalian skin: A mechanism to enhance transdermal drug delivery. Proc. Natl. Acad. Sci. USA90, 10504–10508 (1993).
10.
AbidorI. G., LiL.-H. and HuiS. W.Studies of cell pellets: I. Electrical properties and porosity. Biophys. J.67, 418–426 (1994).
11.
LiL. H., RossP. and HuiS. W.Improving Electrotransfection Efficiency by Post-Pulse Centrifugation. Gene Therapy6, 364–372 (1999).
12.
AbidorI. G., LiL.-H. and HuiS. W.Studies of cell pellets: II. Osmotic properties, electroporation and related phenomena; membrane interactions. Biophys. J.67, 427–435 (1994).
13.
LiL. H., SenA., MurphyS. P., JahreisG. P. and HuiS. W.Apoptosis Induced by DNA Uptake Limits Transfection Efficiency. Exp. Cell Res.253, 541–550 (1999).
14.
NiitsuY., TakahashiY., BanN., TakayamaT., SaitoT., KatahiraT., UmetsuY., NakajimaT., OhiM., KugaT., SakamakiS., MatsunagaT., HirayamaT., KurodaH., HommaH., KatoJ. and KogawaK.A proof of glutathione S-transferase-π-related multidrug resistance by transfer of antisense gene to cancer cells and sense gene to bone marrow stem cell. Chemico-Biological Interactions111–112, 325–332 (1998).
15.
CowanK. H., MoscowJ. A., HuangH., ZujewskiJ., O'ShaughnessyJ., SorrentinoB., HinesK., CarterC., SchneiderE., CusackG., NooneM., DunbarC., SteinbergS., WilsonW., GoldspielB., ReadE. J., LeitmanS. F., McDonaghK., ChowC., AbatiA., ChiangY., ChangeY. N., GottesmanM. M., PastanI., and NienhuisA.Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clinical Cancer Research5, 1619–1628. (1999).
16.
BrennerM. K.Emerging applications of gene transfer in the hematopoietic cancers. J. Pediatric Hematology/Oncology19, 1–6. (1997).
17.
LiL. H., McCarthyP., HuiS. W.High efficienct electrotransfection of human primary hematopoietic stem cells. FASEB J.10, 1096 (2001).
18.
WuM. H., LiebowitaD. N., SmithS. L., WilliamsS. F., DolanE., Efficent expression of foreign genes in human CD34+ hematopoietic precursor cells using electroporation. Gene Therapy8, 384–390 (2001).
19.
Van TendelooV. F., WillemsR., PonsaertsP., LenjouM., NijsG., VanhoveM., MuylaertP., Van CauwelaertP., Van BroeckhovenC., Van BockstaeleD. R., BernemanZ. N.High-level transgene expression in primary human T lymphocytes and adult bone marrow CD34+ cells via electroporation-mediated gene delivery. Gene Ther.7, 1431–7 (2000).
20.
LutzM. B., KukutschN., OgilvieA. L. J., RossnerS., KochF., RomaniN., SchulerG.An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immun Methods223, 77–92 (1999).
21.
GongJ., ChenD., KashiwabaM., KufeD.Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Medicine3, 558–561 (1997).
22.
JuD. W., TaoQ., LouG., BaiM., HeL., YangY., CaoX.Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Res.61, 3735–40 (2001).
23.
HomesL. M., LiJ., SticcaR. P., WagnerT. E., WeiY.A rapid novel strategy to induce tumor cell specific cytotoxic T lymphocyte responses using instant dentritomas. J. Immunotherapy24, 122–4 (2001).
24.
KuglerA., StuhlerG., WaldenP., ZollerG., ZobywalskiA., BossartP., Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Medicine6, 332–336 (2000).
25.
Scott-TaylorT. H., PettengellR., ClarkeI., StuhlerG., La BartheM. C., WaldenP., DalgleishA. G.Human tnmour and dendritic cell hybrids generated by electrofusion: Potential for cancer vaccines. Biochim. Biophys. Acta.1500, 265–279 (2000).
26.
LiL.-H., HensenM. L., ZhaoY.-L., and HuiS. W.Electrofusion between heterogeneous-sized mammalian cells in a pellet: Potential applications in drug delivery and hybridoma formation. Biophys. J.71, 479–486 (1996).
27.
CullanderC.What are the pathways of iontophoretic current flow through mammalian skin?Advanced Drug Delivery Reviews9, 119–135 (1992).
MirL. M., RothC., OrlowskiS., and BelehradekJ.Jr.Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host's defenses. Eur. Cytokine Netw.3, 331–334 (1992).
30.
ZhangL., LiL., HoffmannG. A. and HoffmanR. M.Depth-targeted efficient gene delivery and expression in the skin by pulsed electric fields: An approach to gene therapy of skin aging and other diseases. Biochemical and Biophysical Research Communication220, 633–636 (1996).
31.
SwartzendruberD. C., WertzP. W., KitkoD. J., MadisonK. C., and DowningD. T.Molecular models of the intercellular lipid lamellae in mammalian stratum corneum. Journal of Investigative Dermatology92, 251–257 (1989).
32.
ChizmadzhevY. A., ZarnitsinV. G., WeaverJ. C., PottsR. O.Mechanism of Electroinduced ionic species transport through a multilamellar lipid system. Biophysical J.68, 749–765 (1995).
33.
GalloS. A., SenA., HensenM. L., HuiS. W.Time-dependent ultrastructural changes in porcine stratum corneum following an electric pulse. Biophys. J.76, 2824–2832 (1999).
34.
GalloS. A., SenA., HensaenM. L., HuiS. W.Temperature-dependent electrical and ultrastructural characterization of porcine skin upon electroporation. Biophys. J.82, 109–119 (2002).
35.
PliquettU., VanbeverR., and WeaverJ. C.Local transport regions (LTRs) in human stratum corneum due to long and short high voltage pulses. Bioelectrochem. and Bioenerg.47, 151–161 (1998).
36.
SenA., ZhaoY. L. and HuiS. W.Saturated Anionic Phospholipids Enhance Transdermal Transport by Electroporation. Biophys. J.83, 2064–2073 (2002).
37.
PliquettU., GalloS. A., GusbethC., NeumannE., HuiS. W.Local and Transient Perturbations in Stratum Corneum due to High Voltage Pulses: Contribution of Local Heating. (submitted).
38.
ChenT., SegallE. M., LangerR. and WeaverJ. C.Skin electroporation-rapid measurements of the transdermal voltage and flux of four fluorescent molecules show a transition to large fluxes near 50 V. Journal of Pharmaceutical Sciences87, 1368–1374 (1998).
39.
JohnsonP. G., GalloS. A., OseroffA. R., HuiS. W.Transdermal transport of methylene blue through full-thickness porcine skin by electroporation-electrophoresis. Journal of Investigative Dermatology111, 457–463 (1998).
40.
VanbeverR. and PreatV. V.In vivo efficacy and safety of skin electroporation. Adv. Drug Deliv. Rev.35, 77–88 (1999).
41.
VanbeverR., LangersG., MontmayeurS. and PreatV.Transdermal delivery of fentanyl-rapid onset of analgesia using skin electroporation. Journal of Controlled Release50, 225–235 (1998).
42.
VanbeverR., LecouturierN., PreatV.Transdermal delivery of metoprolol by electroporation. Pharmaceutical Research11, 1657–1662 (1994).
43.
VanbeverR., PreatV., Transdermal delivery, Metoprolol, Membrane permeabilization. Factors affecting transdermal delivery of metoprolol by electroporation. Bioelectrochemistry & Bioenergetics38, 223–228 (1995).
44.
ClarysP., AlewaetersK., JadoulA., BarelA., ManadasR. O. and PreatV.In vitro percutaneous penetration through hairless rat skin: influence of temperature, vehicle and penetration enhancers. European Journal of Pharmaceutics & Biopharmaceutics46, 279–283 (1998).
45.
JadoulA., LecouturierN., MesensJ., CaersW. and PreatV.Transdermal alniditan delivery by skin electroporation. Journal of Controlled Release54, 265–272 (1998).
46.
JadoulA. and PreatV.Electrically enhanced transdermal delivery of domperidone. International Journal of Pharmaceutics154, 229–234 (1997).
47.
VanbeverR., LeroyM. A. and PreatV.Transdermal permeation of neutral molecules by skin electroporation. Journal of Controlled Release54, 243–250 (1998).
48.
RegnierV. and PreatV.Localization of a FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation. Pharm. Res.15, 1596–1602 (1998).
49.
RegnierV., TahiriA., AndreN., LemaitreM., Le DoanT. and PreatV.Electroporation-mediated delivery of 3′-protected phosphodiester oligodeoxynucleotides to the skin. Journal of Controlled Release67, 337–346 (2000).
50.
BommannanD. B., TamadaJ., LeungL. and PottsR. O.Effect of electroporation on transdermal iontophorectic delivery of luteinizing hormone releasing hormone (LHRH) in vitro. Pharmaceutical Research11, 1809–1814 (1994).
51.
VanbeverR., PrausnitzM. R. and PreatV.Macromolecules as novel transdermal transport enhancers for skin electroporation. Pharm. Res.14, 638–644 (1997).
52.
WeaverJ. C., VanbeverR., VaughanT. E. and PrausnitzM. R.Heparin alters transdermal transport associated with electroporation. Biochemical & Biophysical Research Communications234, 637–640 (1997).
53.
ZewertT. E., PliquettU. F., VanbeverR., LangerR. and WeaverJ. C.Creation of transdermal pathways for macromolecule transport by skin electroporation and a low toxicity, pathway-enlarging molecule. Bioelectrochem49, 11–20 (1999).
54.
MisraA., GangaS. and UpadhyayP.Needle-free non-adjuvanted skin immunization by electroporation-enhanced transdermal delivery of diphtheria toxoid and a candidate peptide vaccine against hepatities B. Vaccine18, 517–523 (2000).
55.
LombryC., DujardinN. and PreatV.Transdermal delivery of macromolecules using skin electroporation. Pharm.17, 32–37 (2000).
56.
SenA., ZhaoY. L., ZhangL. and HuiS. W.Enhanced Transdermal Transport by Electroporation using Anionic Lipids. J. Controlled Release82, 399–405 (2002).
57.
IlicL., GowrishankarT. R., VaughanT. E., HerndonT. O. and WeaverJ. C.Spatially constrained skin electroporation with sodium thiosulfate and urea creates transdermal microconduits. Journal of Controlled Release61, 185–202 (1999).
58.
StewartT. P., HuiS. W., PortisA. R.Jr. and PapahadjopoulosD.Complex phase mixing in phosphatidylcholine and phosphatidylserine multilamellar vesicles. Biochim. Biophys. Acta556, 1–16 (1979).
59.
SenA., DalyM. E. and HuiS. W.Transdermal Insulin Delivery Using Lipid-Enhanced Electroporation. Biochim. Biophys. Acta.1564, 5–8 (2002).
60.
ZewertT. E., PliquettU. F., LangerR., WeaverJ. C.Transdermal transport of DNA antisense oligonucleotides by electroporation. Biochem. Biophys. Res. Commun.212, 286–92 (1995).
61.
DoughertyT. J., GomerC. J., HendersonB. W., JoriG., KesselD., KorbelikM., MoanJ., and PengQ.Photodynamic therapy. Journal of the National Cancer Institute90, 889–905 (1998).
62.
JohnsonP. G., HuiS. W., OseroffA. R.Electrically Enhanced Percutaneous Delivery of the Photosensitizer δ-amino Levulinic Acid (ALA) using Electric Pulses and a DC Potential. Photochem. Photobio.75, 534–540 (2002).
63.
Alvarez-FigueroaM. J., Blanco-MendezJ.Transdermal delivery of methotrexate: Iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int. J. Pharm.215, 57–65 (2001).
64.
DisisM. L., CalenoffE., McLaughlinG., MurphyA. E., ChenW., GronerB., JeschkeM., LydonN., McGlynnE., LivingstonR. B., CheeverM. A.Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res.54, 16–20 (1994).
65.
LustgartenJ., TheobaldM., LabadieC., LaFaceD., PetersonP., DisisM. L., CheeverM. A., ShermanL. A.Identification of HER-2/neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Hum Immunol.52, 109–18 (1997).
66.
KonoK., RongcunY., CharoJ., IchiharaF., CelisE., SetteA., AppelaE., SekikawaT., MatsumotoY., KiesslingR.Identification of HER-2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int. J. Cancer78, 202–8 (1998).
67.
DrabickJ. J., Glsddpool-MaloneJ., SomiareS., KingA., MaloneR. W.Cutaneous transfection and immune response to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol. Therapy3, 249–255 (2001).
